StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$515.02−5.64 (-1.08%)

Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –

Vertex Pharmaceuticals Foreign currency cash flow hedge gain reclassified to by Quarter

Foreign currency cash flow hedge gain (loss) reclassified to net product revenues ($M) ($M)

Vertex Pharmaceuticals Foreign currency cash flow hedge gain reclassified to: -$10.2M in Q2 2026, down 52.1% from a year earlier.

Latest, Q2 2026
-10.2
Period ended Jun 30, 2026
Change on a year earlier
-52.1%
-21.3 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
29
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Note (Marketable Securities, Fair Value & Derivative Instruments).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedForeign currency cash flow hedge gain (loss) reclassified to net product revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-10.2-52.1%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 31, 2026-25.5-205.8%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 2025-37.1-251.4%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025-39+1,158.1%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 2025-21.3-295.4%Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 31, 202524.1+608.8%Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 202424.5-975.0%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024-3.10-210.7%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 202410.9+32.9%Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20243.40-84.5%Form 10-Q (filed 2025-05-06) ↗
Q4 2023Dec 31, 2023-2.80-105.4%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 20232.80-95.7%Form 10-Q (filed 2024-11-05) ↗
Q2 2023Jun 30, 20238.20-81.8%Form 10-Q (filed 2024-08-02) ↗
Q1 2023Mar 31, 202322+9.5%Form 10-Q (filed 2024-05-07) ↗
Q4 2022Dec 31, 202252.2+461.3%Form 10-K (filed 2025-02-13) ↗
Q3 2022Sep 30, 202265.2-1,353.8%Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Foreign currency cash flow hedge gain reclassified to ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-fx-hedge-reclass

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?